GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab - Trial NCT06338553
Access comprehensive clinical trial information for NCT06338553 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vanderbilt University Medical Center and is currently Recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vanderbilt University Medical Center
Timeline & Enrollment
Phase 1
Jun 01, 2024
Mar 01, 2027
Primary Outcome
Investigate the impact of GLP-1Ra on postprandial glycemia in a pilot study,Study the impact of GLP-1Ra on the disposition index (DI) in a pilot study,Determine the impact of GLP-1Ra on endothelial function in a pilot study
Summary
The goal of this study is to determine how a drug class called glucagon-like peptide-1
 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes
 undergoing clinical teplizumab treatment. This study involves giving participants a liquid
 meal under three different conditions and observing how their bodies respond, focusing on
 blood sugar levels, insulin effectiveness, and blood vessel function. The first meal test is
 pre-teplizumab, followed by two post-treatment tests, one with the GLP-1Ra drug and the other
 with a placebo. Each test involves blood draws before and during the meal test, GLP-1Ra or
 placebo administration, and an ultrasound to measure blood vessel function. The goal is to
 see if GLP-1Ra can help manage blood sugar levels and improve cardiovascular health in this
 population.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06338553
Non-Device Trial